• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Xspray Pharma

10.90 SEK+2.83 %20/8 11:32
Less than 1K followers

XSPRAY

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
+2.83 %
-27.43 %
-54.96 %
-58.18 %
-64.36 %
-74.06 %
-63.57 %
-90.52 %
-62.89 %

Xspray Pharma is a pharmaceutical company with several product candidates in clinical development that uses the patented HyNap technology to create improved versions of marketed protein kinase inhibitors. The drug candidate Dasynoc® is an amorphous form of dasatinib and is undergoing FDA review for market approval. Xspray Pharma's product portfolio also includes XS003-nilotinib, XS008-axitinib and XS025-cabozantinib.

Read more
Market cap
516.84M SEK
Turnover
1.78M SEK
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
EPS and dividend
Financial calendar
All
Webcasts
Press releases
3rd party
ShowingAll content types

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
4/11
2026

Interim report Q3'26

11/2
2027

Annual report '26

5/5
2027

Interim report Q1'27

Xspray, Press Conference
Webcast2026-08-20 09:00

Xspray, Press Conference

Xspray Pharma
Press release2026-08-19 16:40

Xspray Pharma bjuder in till telefonkonferens med anledning av mottaget CRL för Dasynoc

Xspray Pharma
Press release2026-08-19 16:40

Xspray Pharma invites to a conference call following receipt of CRL for Dasynoc

Xspray Pharma

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release2026-08-19 03:17

Xspray Pharma mottar Complete Response Letter (CRL) från FDA för Dasynoc

Xspray Pharma
Regulatory press release2026-08-19 03:17

Xspray Pharma receives Complete Response Letter (CRL) from FDA for Dasynoc

Xspray Pharma
Press release2026-08-06 12:44

Redeye: Xspray Pharma (Q2 review): Just ahead of Dasynoc PDUFA

Xspray Pharma
Regulatory press release2026-08-05 08:00

Xspray Pharma delårsrapport andra kvartalet 2026

Xspray Pharma
Regulatory press release2026-08-05 08:00

Xspray Pharma Interim Report Second Quarter 2026

Xspray Pharma
Press release2026-06-26 08:35

Xspray Pharma lämnar regulatorisk uppdatering om sina amerikanska läkemedelskandidater Nilopki® och Dasynoc® samt fortsatta framsteg hos kontraktstillverkaren NerPharMa

Xspray Pharma
Press release2026-06-26 08:35

Xspray Pharma provides regulatory update on its US product candidates Nilopki® and Dasynoc® and notes continued progress with its third-party manufacturer NerPharMa

Xspray Pharma
Xspray, Audiocast, Press Release, 2026
Webcast2026-06-08 15:00

Xspray, Audiocast, Press Release, 2026

Xspray Pharma
Press release2026-06-05 16:48

Xspray Pharma bjuder in till telefonkonferens gällande Nilopki™

Xspray Pharma
Press release2026-06-05 16:48

Xspray Pharma to host a conference call regarding Nilopki™

Xspray Pharma
Regulatory press release2026-06-05 00:56

Xspray Pharma mottar CRL från amerikanska FDA för Nilopki™

Xspray Pharma
Regulatory press release2026-06-05 00:56

Xspray Pharma Receives CRL from U.S. FDA for Nilopki™

Xspray Pharma
Press release2026-06-03 16:50

Xspray Pharmas anställda deltar fullt ut i bolagets långsiktiga incitamentsprogram, signalerande stark framtidstro

Xspray Pharma
Press release2026-06-03 16:50

Xspray Pharma employees fully participate in market priced long term incentive programs, signaling strong confidence ahead

Xspray Pharma
Regulatory press release2026-05-12 11:40

Kommuniké från årsstämma i Xspray Pharma AB (publ) 12 maj 2026

Xspray Pharma
Regulatory press release2026-05-12 11:40

Bulletin from the annual general meeting of Xspray Pharma AB (publ) 12 May 2026

Xspray Pharma
Regulatory press release2026-05-04 12:08

Finansinspektionen: Flaggningsmeddelande i XSpray Pharma AB (publ)

Xspray Pharma